Revenue Breakdown
Composition ()
No data
Revenue Streams
Amgen Inc (AMGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other products, accounting for 19.4% of total sales, equivalent to $1.85B. Other significant revenue streams include Prolia and Repatha. Understanding this composition is critical for investors evaluating how AMGN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Amgen Inc maintains a gross margin of 72.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.61%, while the net margin is 13.51%. These profitability ratios, combined with a Return on Equity (ROE) of 106.10%, provide a clear picture of how effectively AMGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AMGN competes directly with industry leaders such as GILD and GMAB. With a market capitalization of $207.92B, it holds a leading position in the sector. When comparing efficiency, AMGN's gross margin of 72.88% stands against GILD's 79.51% and GMAB's 92.34%. Such benchmarking helps identify whether Amgen Inc is trading at a premium or discount relative to its financial performance.
